Click blue titles to view full text in a new window
Use the selectors at the bottom to turn to the next page in the list of documents
Hickman M., Steer C., Tilling K. et al.
Addiction: 2018, 113(8), p. 1461–1476.
Buprenorphine may be associated with a lower risk of mortality than methadone among people engaged in opioid substitution treatment – but is the pattern of short treatment duration in the UK preventing maximal impact at a population level?
Rose A.K., Jones A.
Addiction: 2018, 113(8), p. 1396–1406.
With patchy evidence of the effectiveness of baclofen, and serious concerns about the medication’s safety, is it ‘premature’ for the muscle-relaxant to be prescribed as a treatment for alcohol use disorders?
STUDY 2018 HTM file
Impact of current and scaled-up levels of hepatitis C prevention and treatment interventions for people who inject drugs in three UK settings – what is required to achieve the WHO’s HCV elimination targets?
Ward Z., Platt L., Sweeney S. et al.
Addiction: 2018, 113, p. 1727–1738.
What would it take for the UK to meet the World Health Organization’s target of a 90% reduction in hepatitis C by 2030? According to projections in three diverse areas, current levels of harm reduction services are averting a great deal of transmission, and adding only moderate rates of treatment for hepatitis C would put Britain on course to achieve the elimination target.
Jones A., Pierce M., Sutton M. et al.
Addiction: 2017, 113(2), p. 279–286.
Substance use treatment commissioned on a payment-by-results basis in England has been linked to higher rates of in-treatment abstinence and non-injecting than other commissioning models, but lower rates of treatment initiation and completion. Is this enough to support the policy?
REVIEW 2017 HTM file
Pharmacologically controlled drinking in the treatment of alcohol dependence or alcohol use disorders: a systematic review with direct and network meta-analyses on nalmefene, naltrexone, acamprosate, baclofen and topiramate
Palpacuer C., Duprez R., Huneau A. et al.
Addiction: 2017, in press.
In 2013 nalmefene was authorised for moderating drinking among patients not in need of detoxification, extending pharmacotherapy to less dependent drinkers. Though uniquely authorised for this purpose, this review found other (and probably cheaper) drugs have been just as or possibly more effective, but for none was there high quality evidence.
Zhao J., Stockwell T.
Addiction: 2017, 112, p. 1942–1951.
Minimum price increases of alcoholic beverages in a Canadian province between 2002 and 2013 set the stage for a real-word study of minimum unit pricing. Reductions in alcohol-related hospital admissions, particularly in lower income areas, tentatively suggest that low income regions may experience the greatest health benefits of such a policy.
Bird S.M., McAuley A., Perry S. et al.
Addiction: 2016, 111(5), p.883–891.
In 2011 Scotland became the first country to fund a national policy of distributing the opiate-blocker naloxone to prevent deaths involving opiate-type drugs. According to this evaluation it did prevent deaths where the effect was most likely to be seen – in the weeks after release from prison.
McDonald R., Strang J.
Addiction: 2016, 111, p. 1177–1187.
How confident can we be that take-home naloxone programmes are effective without the ‘gold standard’ randomised trial? Judged against nine criteria for establishing the presumption of causality, evidence that the provision of naloxone reduces overdose-related deaths among opioid users.
Knai C., Petticrew M., Durand M.A. et al.
Addiction: 2015, 1000(8), p. 1217–1225.
At the heart of the UK government’s alcohol strategy are ‘Responsibility Deal’ pledges made by alcohol companies, but rather than being prompted by the deal, this report says actions committed to were usually already done or underway. Other sources suggest the process helped forestall a more effective measure – a minimum per unit price for alcohol.
Mason T., Sutton M., Whittaker W. et al
Addiction: 2015, 110(7), p. 1120–1128.
A flagship drug treatment policy initiative appears to have backfired in England, where the government’s pilot payment-by-results schemes seem to have led to fewer successful completions of treatment and more prospective patients declining treatment.
Select search results pageNEXT 1 2 3 4 5 6 7 8